Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 40%
Hold 35%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is well-positioned for growth with the expansion of its product portfolio, including the new Symplicity Spyral system, and its strong leadership. The company's financials have been consistently strong, and despite potential challenges, analysts have a positive outlook for its future performance. With their upcoming Analyst Day, investors can expect to learn more about the company's long-term growth targets and potential for continued growth in the mid-single-digit range.

Bears say

Medtronic is a leading medical device company that engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. Despite its robust portfolio of products and global presence, Medtronic's stock is likely to face challenges in the near term due to unsuccessful new product launches and potential market share losses in certain product categories. Additionally, the company's growing dependence on state supplemental programs and potential inflationary risks could negatively impact its earnings growth and margins. Overall, our negative outlook is based on the potential for slower revenue and earnings growth, as well as increased competition in key market segments.

Medtronic (MDT) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 40% recommend Buy, 35% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 20 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.